Retraction
A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technology: Development of targeted apoptosis initiators for cancer treatment
Paper Information
Record ID:
45127
Author(s):
Publication Date:
February 08, 2021
Retraction Date:
June 08, 2023
(2.5 years years ago)
Subjects:
Institutions:
- Sci-Engi-Medco Solutions Inc., St Charles, Missouri, United States of America
- Department of Clinical and Molecular Sciences, Section of Experimental and Occupational Medicine, Polytechnic University of Marche, Ancona, Italy
- Molecular Imaging Program at Stanford (MIPS), Canary Center for Cancer Early Detection, Department of Radiology, Stanford University School of Medicine, Palo Alto, California, United States of America
- Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, United States of America
- Department Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
Countries:
Article Type:
Publisher:
PLoS
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1371/journal.pone.0287148Citations (5)
5
Total Citations0
Post-Retraction3
Pre-Retraction1
Same DayHeavy Metals Removal Using Carbon Based Nanocomposites
Unknown Authors
Unknown Journal
Published: Unknown
Retraction: A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technology: Development of targeted apoptosis initiators for cancer treatment
Unknown Authors
PLoS ONE
Open Access
Published: Jun 2023
Same day as retraction
Medicago Sativa Defensin1 as a tumor sensitizer for improving chemotherapy: translation from anti-fungal agent to a potential anti-cancer agent
Raghu S. Pandurangi, Amol Karwa, Uma Shankar Sagaram et al. (5 authors)
Frontiers in Oncology
Open Access
Published: May 2023
9 citations
9 citations
13 days before retraction
Rational Drug Design of Targeted and Enzyme-Cleavable Vitamin E Analogs as a Neoadjuvant to Chemotherapy: <i>In Vitro</i> and <i>In Vivo</i> Evaluation on Reduction of the Cardiotoxicity Side Effect of Doxorubicin
Raghu S. Pandurangi, Orsolya Cseh, H. Artee Luchman et al. (6 authors)
ACS Pharmacology & Translational Science
Open Access
Published: Feb 2023
6 citations
6 citations
122 days before retraction
Rational Drug Design of Targeted and Enzyme Cleavable Vitamin E Analogs as Neoadjuvant to Chemotherapy: In Vitro and In Vivo Evaluation on Reduction of Cardiotoxicity of Doxorubicin.
Raghu S. Pandurangi, Orsolya Cseh, Artee Luchman et al. (7 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: May 2021
1 citation
1 citation
748 days before retraction
Quick Stats
Total Citations:
8
Years Since Retraction:
2.5 years
Open Access:
Yes
Last Checked:
Jul 24, 2025